According to a market report by Lucintel, the future of the global avascular necrosis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global avascular necrosis market is expected to reach an estimated $853.8 million by 2030 from $608.8 million in 2024,at a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are growing preference for less painful substitute bone grafting surgical procedures, rising preference for surgeries to treat osteonecrosis, and increasing adoption of nonsteroidal anti-inflammatory drugs.
A more than 150-page report to understand trends, opportunity and forecast in avascular necrosis market to 2030 by type (trauma and non-trauma), treatment (nonsteroidal anti-inflammatory drugs (NSAIDs), cholesterol lowing drugs, osteoporosis drugs, blood thinners, and others), diagnosis (imaging, biopsy, CT scan, PET, and x- ray), end use (hospital pharmacies, retail pharmacies, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that non-trauma will remain the larger segment over the forecast period due to its rising usage among various treatments related to alcohol intake and abnormalities related to metabolism of bones.
Within this market, hospital pharmacy is expected to witness the highest growth due to increasing number of hospitalized patients opting for non-invasive therapy and surgery to treat osteonecrosis.
Download sample by clicking on avascular necrosis market
In terms of regions, North America will remain the largest region over the forecast period due to rising cases of avascular necrosis among individuals, an increase in the geriatric population, and the presence of key players in the region.
Novartis, copyright, Teva Pharmaceutical, Mylan, Zimmer Biomet, Merck, EnzoBiochem, Atnahs, Bone Therapeutics, Vericel are the major suppliers in the avascular necrosis market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected]To get access of more than 1000 reports at fraction of cost visit Lucintel'sAnalytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market &unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1-972-636-5056
Explore Our Latest Publications
Blister Packaging Equipment Market
Cloud Workload Protection Market
Comments on “Lucintel Forecasts the Global Avascular Necrosis Market to Reach $853.8 million by 2030”